Evaluation of the acute effects of inhaled iloprost on aortic compliance in pulmonary arterial hypertension using invasive methods
- 1 April 2025
- journal article
- research article
- Published by Springer Nature in Herz
- Vol. 50 (5) , 385-394
Abstract
Background Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and elevated pulmonary vascular resistance. Aortic compliance indicates vascular stiffness and may be increased in PAH. Inhaled iloprost, a prostacyclin analog, is commonly used for PAH treatment and vasoreactivity testing. Its acute effects on aortic compliance remain unclear. This study evaluated the immediate impact of inhaled iloprost on aortic compliance through aortic pulse wave velocity (aPWV) measurements and pressure parameters in patients with PAH undergoing right heart catheterization. Methods This single-center, cross-sectional study enrolled patients with group 1 PAH who underwent right heart catheterization with pulmonary vasoreactivity testing between August 2022 and May 2023. Aortic compliance was measured via aPWV before and after inhaling 20 mcg/mL iloprost. On the basis of the post-iloprost changes, 32 patients were categorized into high-aPWV (n = 4) or low-aPWV (n = 28) groups. Multivariate regression analysis identified significant predictors of impaired aortic stiffness. Results The median patient age was 54.5 years (42.2–60.5). No significant differences were found between groups regarding percentage reductions in proximal/distal aortic pressure and pulmonary artery pressure after iloprost administration. The QRS interval was a significant predictor of impaired aortic stiffness (odds ratio: 1.072, 95% confidence interval: 1.002–1.197, p = 0.045). The high-aPWV group demonstrated significantly lower QRS intervals compared to the low-aPWV group (79.0 ms [70.5–84.0] vs. 96.0 ms [85.5–102.0], p = 0.011). Conclusions Inhaled iloprost effectively reduced both aortic pressure and pulmonary artery pressure regardless of aortic compliance in patients with group 1 PAH. The QRS interval emerged as an independent predictor of impaired aortic stiffness, offering potential for risk stratification in clinical practice.Keywords
This publication has 25 references indexed in Scilit:
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Prolonged QRS DurationChest, 2012
- AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the ElectrocardiogramJACC, 2009
- Inhaled iloprost for the treatment of pulmonary hypertensionEuropean Respiratory Review, 2009
- A USA-based registry for pulmonary arterial hypertension: 1982–2006European Respiratory Journal, 2007
- The effects of hypoxia on the cells of the pulmonary vasculatureEuropean Respiratory Journal, 2007
- Pulmonary Arterial Hypertension in FranceAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Iloprost for idiopathic pulmonary arterial hypertensionExpert Review of Cardiovascular Therapy, 2005
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During ExerciseChest, 2002